EARS News and Press, Auris Medical Holding AG From 01/10/20

Sorrento Therapeutics (NASDAQ: SRNE ) +50%  on non-binding takeover bid . More news on: Sorrento Therapeutics, Inc., Aclaris Therapeutics, Inc., AzurRx BioPharma, Inc., Stocks on the move, Read more ...

Received “Intention to Grant” notice from European Patent Office Application covers invention of oral treatment for tinnitus Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeut...

Sol-Gel Technologies (NASDAQ: SLGL ) +160%  on Twyneo successful in acne studies. More news on: Sol-Gel Technologies Ltd., Savara Inc., NIO Limited, Stocks on the move, Read more ...

Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the formation of a ne...

Gainers: NF Energy Saving (NASDAQ: BIMI ) +286% . Synthesis Energy Systems (NASDAQ: SES ) +156% . Yuma Energy (NYSEMKT: YUMA ) +58% . Ideal Power (NASDAQ: IPWR ) +34% . Oncternal Therapeutics (NASDAQ: ONCT ) +31% . Bio-Path Holdings (NASDAQ: BPTH ) +21% . Enochian Biosciences (NASDA...

Gainers: Synthesis Energy Systems (NASDAQ: SES ) +81% . MOGU (NYSE: MOGU ) +20% . Purple Innovation (NASDAQ: PRPL ) +19% . Fastenal (NASDAQ: FAST ) +17% . Aerie Pharmaceuticals (NASDAQ: AERI ) +17% . Valaris (NYSE: VAL ) +16% . Mmtec (NASDAQ: MTC ) +15% . Aclaris Therapeutics (NASD...

Thinly traded nano cap Auris Medical Holding (NASDAQ: EARS ) perks up  2%  premarket on increased volume, albeit on turnover of only 59K shares, in reaction to interim results from a Phase 1b clinical trial evaluating AM-201, a betahistine nasal spray, for the treatment of antips...

Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced positive interim resu...

Auris Medical Holding ( EARS +3.4% ) announces that the FDA and EMA are both on board with the use of the Tinnitus Functional Index (TFI) as the primary efficacy endpoint for its planned Phase 2/3 clinical trial evaluating Keyzilen (AM-101) in patients with the chronic ear-ringing condit...

Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it has obtained...